Figure 6 Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study Figure 6| Pharmacodynamic profile.

Slides:

Advertisements

Similar presentations

Inhibitory Effects of Ticagrelor Compared to Clopidogrel on Platelet Function in Patients with Acute Coronary Syndromes The PLATO PLATELET Substudy Storey.

Advertisements

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Patients With Poor Responsiveness to Thienopyridine.

Adapted from Angiolillo DJ et al. Am J Cardiol. 2006;97: Individual Response Variability to Dual Antiplatelet Therapy in the Steady State Phase of.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impaired Responsiveness to the Platelet P2Y 12 Receptor.

Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI

Nat. Rev. Cardiol. doi: /nrcardio

Francesco Franchi, MD, Fabiana Rollini, MD, Jose Rivas Rios, MD, Andrea Rivas, MD, Malhar Agarwal, MD, Megha Kureti, MD, Deepa Nagaraju, MD, Mustafa Wali,

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Metabolism pathway of antiplatelet agents

Figure 2 Different manifestations of myocardial ischaemia

Figure 4 Activation of clopidogrel via cytochrome P450

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

Figure 2 Binding properties of P2Y12-receptor inhibitors

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 BMI and cardiorespiratory fitness levels

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Pharmacodynamic comparison of crushed versus integral

Figure 4 BMI and mortality in patients with heart failure

Figure 1 Energy supply–demand matching in health and heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Global rates of sodium, fruit, and vegetable intake

Figure 1 Anatomy of the femoral artery

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Three-year survival rates on the basis of body composition

Nat. Rev. Cardiol. doi: /nrcardio

Figure 8 4D magnetic resonance imaging patterns

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Figure 2 Imaging of atherosclerotic plaque burden

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Health-care system today

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Cardiovascular risk and disease across the life-course

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Decision tree integrating the assessment,

Figure 3 Neural crest cell migration

Figure 2 Global cost of HF per capita in 2012

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 The neurogenic components of angina

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Platelet receptors and available pharmaceutical options

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Impaired mitochondrial capacity and function in heart failure

Roberta Rossini et al. JCIN 2018;11:

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Fourteen (28%) of 50 patients met the criteria of nonresponse with test results of over 52 AU. Patient 1 received a second full loading dose of 300 mg.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Presentation transcript:

Figure 6 Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study Figure 6| Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study.58 P2Y12 reaction units in clopidogrel-nonresponsive patients before and after crossover. Patients treated with ticagrelor in period 1 received a 600 mg clopidogrel loading dose followed by 75 mg daily maintenance therapy in period 2; patients treated with clopidogrel in period 1 received a 180 mg ticagrelor loading dose followed by 90 mg twice-daily maintenance therapy in period 2. *P <0.0001. ‡P <0.05. Reprinted from Gurbel, P. A. et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121 (10), 1188–1199 (2010), with permission from Wolters Kluwer Health and the American Heart Association. Reprinted from Gurbel, P. A. et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121 (10), 1188–1199 (2010), with permission from Wolters Kluwer Health and the American Heart Association Rollini, F. et al. (2015) Switching P2Y12-receptor inhibitors in patients with coronary artery disease Nat. Rev. Cardiol. doi:10.1038/nrcardio.2015.113